IXP Launches Maiden Rs 2 Bn Fund to Fuel Biotech Innovation

14 Feb 2025 CW Team

The IXP Lifesciences Catalyst Fund is targeting a corpus of Rs 2 billion with a greenshoe option of Rs 1 billion. The fund plans to create a portfolio of 20-25 companies addressing gaps in the market for both services and products. Within the Lifesciences sector, the fund will invest across innovation in areas such as pharma, biotechnology, medical technology, speciality chemicals, agrotechnology and nutraceuticals.

Ketki Tulpule, Ph.D., CIO at IXP said, “IXP was born out of a need we saw in the Indian start-up ecosystem. In fact, we conducted a pan-India survey to understand the pain points of biotech’s for an outside-in perspective. The sector is nuanced, and requires investors with scientific expertise, industry knowledge, and operational experience to help biotech’s succeed. We are glad to have onboarded industry veterans as council members and advisors who add to the scientific heft of the fund”.

Vishal Goel, Partner at IXP and Co-founder of JV Ventures commented, “The Indian Lifesciences industry is dynamic with large untapped potential. Through IXP Venture Studio, we will co-create companies along with scientists for ideas addressing unmet needs in the market. Unlike traditional VCs, IXP has a hands-on approach through active participation from concept to scale. The Ventureprenuer Program has been designed to transform scientists into founders”.

Jasmeet Chhabra, Partner at IXP and Co-founder of JV Ventures added, “The success of biotech’s hinges on many factors, not just capital. These early-stage companies require access to larger ecosystems for laboratories, networks and R&D services which we provide through PoweRx, the Lifesciences vertical of JV Ventures. This differentiates IXP from other funds as it leverages synergies within the group to create a winning proposition for portfolio companies.”

Image Source:https://www.msn.com/

IXP, a Lifesciences VC backed by JV Ventures, has announced the launch of it’s first fund to invest in early-stage companies. The fund aims to build a portfolio of B2B companies ranging from Pre-seed to Series A stages. The IXP Lifesciences Catalyst Fund is targeting a corpus of Rs 2 billion with a greenshoe option of Rs 1 billion. The fund plans to create a portfolio of 20-25 companies addressing gaps in the market for both services and products. Within the Lifesciences sector, the fund will invest across innovation in areas such as pharma, biotechnology, medical technology, speciality chemicals, agrotechnology and nutraceuticals. Ketki Tulpule, Ph.D., CIO at IXP said, “IXP was born out of a need we saw in the Indian start-up ecosystem. In fact, we conducted a pan-India survey to understand the pain points of biotech’s for an outside-in perspective. The sector is nuanced, and requires investors with scientific expertise, industry knowledge, and operational experience to help biotech’s succeed. We are glad to have onboarded industry veterans as council members and advisors who add to the scientific heft of the fund”. Vishal Goel, Partner at IXP and Co-founder of JV Ventures commented, “The Indian Lifesciences industry is dynamic with large untapped potential. Through IXP Venture Studio, we will co-create companies along with scientists for ideas addressing unmet needs in the market. Unlike traditional VCs, IXP has a hands-on approach through active participation from concept to scale. The Ventureprenuer Program has been designed to transform scientists into founders”. Jasmeet Chhabra, Partner at IXP and Co-founder of JV Ventures added, “The success of biotech’s hinges on many factors, not just capital. These early-stage companies require access to larger ecosystems for laboratories, networks and R&D services which we provide through PoweRx, the Lifesciences vertical of JV Ventures. This differentiates IXP from other funds as it leverages synergies within the group to create a winning proposition for portfolio companies.” Image Source:https://www.msn.com/

Infrastructure Transport

07 Apr 2026

Tunnelling Begins for Thane, Borivali twin tunnel project

Tunnelling work has commenced for the 11.84-km Thane–Borivali Twin Tunnel, set to be India’s longest urban road tunnel, marking a key milestone in Mumbai’s infrastructure development.As per a post shared by Mumbai Metropolitan Region Development Authority on social media platform X, the tunnel boring machine (TBM) ‘Nayak’—the country’s largest single-shield hard rock TBM for an urban tunnel—was launched by Devendra Fadnavis on Tuesday. The event was attended by Eknath Shinde and Sunetra Pawar, among other dignitaries. A second TBM, ‘Arjuna’, is expected to be launched so..

Infrastructure Transport

07 Apr 2026

Large Format Store Planned At M G Road Metro Station

M G Road station in Bengaluru is set to host the city’s first large-format commercial and experience space, with planning led by Bangalore Metro Rail Corporation Limited. BMRCL has invited proposals to develop and operate a central business district destination at the Purple?Pink Line interchange. The plan positions the station as a commercial hub designed to serve a broad commuter base across the city. The proposal is part of a broader effort to activate transit nodes commercially. Tender documents set a minimum monthly rental of Rs 0.944 million (mn), inclusive of GST, for the large-format..

Infrastructure Energy

07 Apr 2026

Government Cancels Auction Of Eleven Critical Mineral Blocks

The government has cancelled the auction of 11 critical and strategic mineral blocks after receiving a poor investor response and failing to attract a sufficient number of qualified bidders. The decision represents a setback to plans to ramp up domestic exploration and production of critical minerals amid global supply chain disruptions and rising demand for materials used in clean energy and advanced technologies. The mines ministry issued an annulment notice setting out the reasons for the cancellations. The annulment notice indicated that the auction process for five mineral blocks was canc..